Showing 1161-1170 of 1395 results for "".
- Glaukos Announces Clinical Milestone of 200 Peer-Reviewed Publications on iStent Technologieshttps://modernod.com/news/glaukos-announces-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies/2479463/Glaukos announced a clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for any MIGS procedure, according to Glau
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Systematic Review of Standalone iStent Trabecular Micro-Bypass Glaucoma Surgeryhttps://modernod.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/A new meta-analysis of the iStent and iStent inject (Glaukos) found that standalone trabecular micro-bypass glaucoma surgery with the devices is associated with clinically relevant reductions in intraocular pressure. The focus of the study, which was published in the Journal of Glaucom
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- Prevent Blindness Issues Call for Nominations for Two Awardshttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-two-awards/2478723/Prevent Blindness has issued the call for nominations for the “
- CMS Issues Final 2021 ASC Payment Rule: 2.4% Increase for Facilitieshttps://modernod.com/news/cms-issues-final-2021-asc-payment-rule-2-4-increase-for-facilities/2478624/On December 2, the Centers for Medicare and Medicaid Services (CMS) issued its final CY 2021 payment rate regulation for hospital outpatient departments (HOPD) and ambulatory surgery centers (ASC). ASC Payme
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- iSTAR Medical Reports Positive 6-Month Data for MINIject Devicehttps://modernod.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/iSTAR Medical announced that its microinvasive glaucoma surgery (MIGS) device MINIject showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supracilia